Seroxat and the suppression of clinical trial data: Regulatory failure and the uses of legal ambiguity

A fascinating paper was sent to me anonymously regarding the MHRA investigation into GlaxoSmithKline.

It opens a door that I never really thought about and begs the question:

Did the MHRA fail to prosecute GSK because a high-profile criminal trial would have highlighted the regulators faults and processes?

Extract:

"Seen in this light, it could even be argued that defects in the
regulatory scheme were convenient for the regulator. Instead of
blaming its own structures and mechanisms, or, perhaps worse,
having to face a high-profile criminal trial in which GSK’s
lawyers would skilfully pick over documents, memos and
emails, in minute detail, in order to find fault with the regulator
and its processes, the MHRA has been able to avoid these
threats to its reputational status by blaming shoddy statutory
drafting."

More coming soon.

Fid

Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING